Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.10.0.1
SEGMENT INFORMATION (Tables)
3 Months Ended 9 Months Ended
Aug. 31, 2018
Aug. 31, 2017
Aug. 31, 2018
Aug. 31, 2017
Schedule of Segment Information [Table Text Block]
                Corporate        
                and        
    CDMO     CT     Eliminations     Consolidated  
    (in thousands)  
Revenues from external customers $ 8,092   $ 83   $ (1,945 ) $ 6,230 *  
Cost of revenues   (3,908 )   -     539     (3,369 )
Segment gross profit (loss)   4,184     83     (1,406 )   2,861  
Research and development expenses, net   (245 )   (3,298 )   1,406     (1,737 )
Operating expenses   (1,712 )   (1,453 )         (3,165 )
Other expenses   (88 )   -           (88 )
Segment operating profit (loss)   2,139     (4,268 )   -     (2,129 )
Adjustments to presentation of segment                        
Adjusted EBIT                        
     Depreciation and amortization   (567 )   (3 )            
Segment performance   1,572     (4,271 )            
                Corporate        
                and        
    CDMO     CT     Eliminations     Consolidated  
    (in thousands)  
Net revenues from external customers $ 2,956           (394 )   2,562  
Cost of revenues   (1,439 )         95     (1,344 )
Segment gross profit (loss)   1,517           (299 )   1,218  
Research and development expenses, net         (688 )   299     (389 )
Operating expenses   (1,641 )   (1,272 )         (2,913 )
Segment operating profit (loss)   (124 )   (1,960 )   -     (2,084 )
Adjustments to presentation of segment                        
Adjusted EBIT                        
Depreciation and amortization expense   (945 )                  
Segment Performance   (1,069 )   (1,960 )            
                Corporate        
                and        
    CDMO     CT     Eliminations     Consolidated  
    (in thousands)  
Revenues from external customers $ 15,807   $ 83   $ (3,037 ) $ 12,853 *  
Cost of revenues   (7,826 )   -     927     (6,899 )
Segment gross profit (loss)   7,981     83     (2,110 )   5,954  
Research and development expenses, net   (245 )   (4,764 )   2,110     (2,899 )
Operating expenses   (3,895 )   (4,448 )         (8,343 )
Other income   228     -           228  
Segment operating profit (loss)   4,069     (9,129 )   -     (5,060 )
Adjustments to presentation of segment                        
Adjusted EBIT                        
     Depreciation and amortization   (1,807 )   (7 )            
Segment performance   2,262     (9,136 )            
                Corporate        
                and        
    CDMO     CT     Eliminations     Consolidated  
    (in thousands)  
Revenues from external customers $ 7,705   $   -   $ (993 ) $ 6,712  
Cost of revenues   (4,358 )         403     (3,955 )
Segment gross profit (loss)   3,347           (590 )   2,757  
Research and development expenses, net         (1,932 )   590     (1,342 )
Operating expenses   (916 )   (6,060 )         (6,976 )
Segment operating profit (loss)   2,431     (7,992 )   -     (5,561 )
Adjustments to presentation of segment                        
Adjusted EBIT                        
Depreciation and amortization expenses   (2,145 )   (7 )            
Segment Performance   286     (7,999 )            
Schedule Of Reconciliation of Segment Performance [Table Text Block]
    Three Months  
    Ended August  
    31, 2018  
    in thousands  
  Segment performance   (2,699 )
Stock-based compensation   (955 )
Financial expenses, net   (1,070 )
Share in losses of associated companies   (202 )
Net gain on remeasurement of previously 
     equity interest in Atvio and CureCell to 
     acquisition date fair value
  4,509  
Transaction expenses related to GPP agreement   (1,500 )
Loss before income tax $ (1,917 )
    Three  
    Months  
    Ended  
    August 31,  
    2017  
    in thousands  
Segment performance   (3,029 )
Stock-based compensation   (383 )
Financial expenses, net   45  
Share in losses of associated companies   (152 )
Loss before income tax   (3,519 )
    Nine months  
    Ended August  
    31, 2018  
    in thousands  
Segment performance   (6,874 )
Stock-based compensation   (2,782 )
Financial expenses, net   (3,164 )
Net gain on remeasurement of previously
     equity interest in Atvio and CureCell to 
     acquisition date fair value
  4,509  
Transaction expenses related to GPP agreement   (1,500 )
Share in losses of associated companies   (732 )
Loss before income tax $ (10,543 )
    Nine Months  
    Ended  
    August 31,  
    2017  
    in thousands  
Segment performance   (7,713 )
Stock-based compensation   (1,469 )
Financial expenses, net   (2,534 )
Share in losses of associated companies   (348 )
Loss before income tax   (12,064 )
Schedule of Revenues from Major Customers [Table Text Block]    
    Nine Months Ended     Three Months Ended  
    August 31,     August 31,     August 31,     August 31,  
    2018     2017     2018     2017  
    (in thousands)  
Customer A $ 2,339   $ 852   $   -   $ 2,813  
Customer B $ 3,922   $   -   $ 1,651   $   -  
Customer C $ 3,109   $ 809   $ 956   $ 1,904  
Customer D $   -   $ 679   $   -   $ 1,637  
Customer E $   -   $   -   $ 1,100   $   -  
Customer F $   -   $   -   $ 784   $   -